Rajeev Dhere News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rajeev dhere. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rajeev Dhere Today - Breaking & Trending Today

Serum Institute's meningococcal vaccine gets WHO prequalification

Serum Institute's meningococcal vaccine gets WHO prequalification
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Adar Poonawalla , World Health Organisation , Serum Institute Of India , Vaccine Alliance , Development Office , United Nations , Serum Institute , Rajeev Dhere ,

Explained: What is Pneumosil, India's first indigenously created vaccine against pneumococcal disease?


Explained: What is India’s first indigenously created vaccine against pneumococcal disease?
Pneumococcal disease is a significant contributor under-five mortality rate worldwide.
Updated: January 1, 2021 12:44:47 pm
The vaccine, Pneumosil, will be available shortly. (Serum Institute of India)
Pune-based Serum Institute of India (SII)
unveiled India’s first indigenously developed pneumococcal vaccine on Monday. The world’s largest vaccine manufacturer by doses, SII is also the maker of Covishield, the Indian version of the AstraZeneca-Oxford coronavirus vaccine.
SII’s pneumococcal vaccine, Pneumosil, was developed through a collaboration spanning over a decade with the health organisation PATH and the Bill and Melinda Gates Foundation. The vaccine was launched by Union Health Minister Dr Harsh Vardhan. “This is a significant milestone for the country’s public healthcare which will ensure that children are pro ....

Adar Poonawalla , Union Health , World Health Organization , Serum Institute , Melinda Gates Foundation , Serum Institute Of India , Pune Based Serum Institute , Melinda Gates , Union Health Minister Dr Harsh , Harsh Vardhan , Rajeev Dhere , Drugs Controller General , Advance Market Commitment , Pneumosil Vaccine , What Is Pneumosil , Pneumococcal Disease , What Is Pneumococcal Disease , Indian Express , அடார் பூனாவல்ல , தொழிற்சங்கம் ஆரோக்கியம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , சீரம் நிறுவனம் , மெலிண்டா வாயில்கள் அடித்தளம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , புனே அடிப்படையிலானது சீரம் நிறுவனம் , மெலிண்டா வாயில்கள் ,

India's first indigenously developed pneumococcal vaccine launched | India News,The Indian Express


India’s first indigenously developed pneumococcal vaccine launched
This is a significant milestone for the country s public healthcare which will ensure that children are protected better against pneumococcal disease with an effective vaccine, Dr Harsh Vardshan said at the virtual launch function on Monday.
Updated: December 28, 2020 8:47:26 pm
Spokespersons of Pfizer, Moderna and AstraZeneca have clarified that pork products are not part of their Covid-19 vaccines. (AP)
Union Health Minister Dr Harsh Vardhan on Monday launched India’s first fully indigenously developed pneumococcal vaccine “Pneumosil”. Serum Institute of India, the largest vaccine manufacturer in the world by doses, developed Pneumosil through a collaboration spanning over a decade with PATH and Bill and Melinda Gates Foundation. ....

Cyrus Poonawalla , Adar Poonawalla , Union Health , Melinda Gates Foundation , Serum Institute Of India , Union Health Minister Dr Harsh Vardhan , Melinda Gates , Harsh Vardshan , Serum Institute , Rajeev Dhere , Executive Director , Advance Market Commitment , சைரஸ் பூனாவல்ல , அடார் பூனாவல்ல , தொழிற்சங்கம் ஆரோக்கியம் , மெலிண்டா வாயில்கள் அடித்தளம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , தொழிற்சங்கம் ஆரோக்கியம் அமைச்சர் டாக்டர் கடுமையான வர்தன் , மெலிண்டா வாயில்கள் , சீரம் நிறுவனம் , ராஜீவ் தேரே , நிர்வாகி இயக்குனர் ,

Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19


Share this article
Share this article
NEW YORK and PUNE, India, Dec. 14, 2020 /PRNewswire/ Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix s Synthetic Attenuated Virus Engineering (
SAVE) platform that uses synthetic biology to re-code the genes of viruses into safe and stable vaccines. COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus. ....

United Kingdom , City Of , Johanna Bennett Ingrid Mezo , Steffen Mueller , Mayank Sen , J Robert Coleman , Eckard Wimmer At Stony Brook University , Prnewswire Codagenix Inc , Serum Institute Of India Pvt , National Academy Of Science , Healthcare Products Regulatory Agency , Serum Institute Of India , Codagenix Inc , Serum Institute , Synthetic Attenuated Virus Engineering , Rajeev Dhere , Executive Director , National Academy , Eckard Wimmer , Stony Brook University , Adjuvant Capital , Topspin Partners , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஸ்டெஃபென் முல்லர் , மயங்க் சென் ,